Matches in Wikidata for { <http://www.wikidata.org/entity/Q63817872> ?p ?o ?g. }
Showing items 1 to 38 of
38
with 100 items per page.
- Q63817872 description "clinical trial" @default.
- Q63817872 description "ensayu clínicu" @default.
- Q63817872 description "klinisch onderzoek" @default.
- Q63817872 description "клінічне випробування" @default.
- Q63817872 name "Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment" @default.
- Q63817872 type Item @default.
- Q63817872 label "Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment" @default.
- Q63817872 prefLabel "Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment" @default.
- Q63817872 P1050 Q63817872-6E6F63AB-FEAC-4115-AA47-012DF218C3AE @default.
- Q63817872 P1132 Q63817872-D2E8A53D-1B0E-4FC1-A126-DB60A2BEB20C @default.
- Q63817872 P1476 Q63817872-0BD8E7A3-E864-464F-A602-52AB387A2F38 @default.
- Q63817872 P17 Q63817872-5FEFB8DB-46C3-4F30-8094-AEE2E963623C @default.
- Q63817872 P1813 Q63817872-35FC4A20-B0D0-4277-BEBA-49D63D0BAA58 @default.
- Q63817872 P2899 Q63817872-F8405C96-5FFD-498C-93C4-F19D0D075512 @default.
- Q63817872 P3098 Q63817872-6BE2D210-23DC-42CF-B2A3-D813BEC1D42B @default.
- Q63817872 P31 Q63817872-CC56A52F-1CFB-4770-9E71-087DB686B6AE @default.
- Q63817872 P4844 Q63817872-541DB0C6-B962-4FA5-A042-1BDBE3E34218 @default.
- Q63817872 P580 Q63817872-CC1CB85C-844D-4BFB-A999-E58E9D3FCBC2 @default.
- Q63817872 P582 Q63817872-0816A0BC-6166-497B-90D7-CBED501D9794 @default.
- Q63817872 P6099 Q63817872-1023C336-878F-4824-8E9B-F92025AD2335 @default.
- Q63817872 P6153 Q63817872-FB025601-210C-43C6-81AD-5829F0E5A8E1 @default.
- Q63817872 P8363 Q63817872-31E8DBD7-2232-4EFD-B462-98A0659187D5 @default.
- Q63817872 P859 Q63817872-DE386877-23B9-4670-9008-8578D30F3CFD @default.
- Q63817872 P1050 Q631361 @default.
- Q63817872 P1132 "+111" @default.
- Q63817872 P1476 "Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment. A UK, 18-month, Prospective, Open-label, Multicentre, Single-arm, Phase IIIb Study With 12-month Primary Endpoint, Assessing the Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Diabetic Macular Oedema." @default.
- Q63817872 P17 Q145 @default.
- Q63817872 P1813 "RELIGHT" @default.
- Q63817872 P2899 "+18" @default.
- Q63817872 P3098 "NCT01257815" @default.
- Q63817872 P31 Q30612 @default.
- Q63817872 P4844 Q414270 @default.
- Q63817872 P580 "2011-01-01T00:00:00Z" @default.
- Q63817872 P582 "2013-04-01T00:00:00Z" @default.
- Q63817872 P6099 Q42825046 @default.
- Q63817872 P6153 Q507154 @default.
- Q63817872 P8363 Q78089383 @default.
- Q63817872 P859 Q507154 @default.